White & Case Advises FSN Capital on Acquisition of Adragos Pharma

Press Release
1 min read

Global law firm White & Case LLP has advised FSN Capital on its acquisition of Adragos Pharma, a globally operating contract development and manufacturing organization (CDMO).

"This transaction illustrates our ability to coordinate and swiftly execute on complex cross-border transactions, and adds another deal to the successful White & Case track record in the pharmaceutical & healthcare sector," said White & Case partner Johan Steen, who led the Firm’s deal team.

FSN Capital is a leading private equity adviser in the Northern European region with a focus on making control investments. Headquartered in Germany and operating globally, Adragos Pharma is a CDMO with sites in France, Germany and Japan focused on the production of finished dosage form in the small molecule segment and providing end-to-end services for its pharma customers. 

The White & Case team which advised on the transaction was led by partner Johan Steen (Stockholm) and included partners Stefan Koch, Bodo Bender (both Frankfurt), Guillaume Vitrich, Alexandre Jaurett (both Paris) and Jun Usami (Tokyo), local partners Hugo Schwarz Leite (Frankfurt) and Thilo Wienke (Düsseldorf), and associates Victor Åberg, Niki Yahyavi (both Stockholm), Stefania Sacuiu, Louise Lundberg, Philippe Hendrickx, Edouard de Walque (all Brussels), Thorsten Rohde, Lea Kaase, Robin Jackson, Alexander Sansotta (all Frankfurt), Kristin Brüggert (Hamburg), Thomas Jacques (Dubai) and Marina Tatsumi (Tokyo).

Press contact
For more information please speak to your local media contact.